Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sernova Corp (OP: SEOVF )

0.2802 +0.0162 (+6.14%)
Streaming Delayed Price Updated: 10:55 AM EDT, Jun 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,957
Open 0.2850
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.2640
Today's Range 0.2802 - 0.2850
52wk Range 0.1961 - 0.8060
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sernova Provides Positive Clinical and Platform Portfolio Update
With recent positive findings in post-surgical hypothyroidism large animal study, Sernova anticipates filing an Investigational New Drug (IND) application in 2024 
Via TheNewswire.com
Sernova Announces Peer Reviewed Publication Demonstrating Safety and Efficacy of a Novel Cell Pouch Cell Therapy Approach for Treatment of Severe Hemophilia A
LONDON, ONTARIO – TheNewswire - January 20, 2022 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine and cell therapy therapeutics company developing a... 
Via TheNewswire.com

Performance

YTD
-48.81%
-48.81%
1 Month
+16.75%
+16.75%
3 Month
-31.84%
-31.84%
6 Month
-45.08%
-45.08%
1 Year
-58.79%
-58.79%

More News

Read More
Sernova to Present Corporate Update at Canaccord Genuity's 41st Annual Growth Conference
Via TheNewswire.com
Exposures COVID-19
Sernova Announces 2021 Annual Meeting Results: Shareholders Approve Resolutions with Overwhelming Majority
Via TheNewswire.com
Exposures COVID-19
Industry Veteran Frank Shannon Joins Sernova as VP Clinical Development and Regulatory Affairs
Via TheNewswire.com
Exposures COVID-19
Sernova's Principal Investigator Presents Interim Data and Positive Patient Outcomes of Phase I/II T1D Study at the American Diabetes Association 81st Scientific Sessions
Via TheNewswire.com
Exposures COVID-19
Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference
Via TheNewswire.com
Exposures COVID-19
Sernova Announces American Transplant Congress 2021 Virtual Connect Abstract Presentation
Via TheNewswire.com
Exposures COVID-19
Sernova to Present at Global Partnership Family Office -- HealthCare & Biotechnology TSX Showcase
Via TheNewswire.com
Sernova Announces the Nomination of Seasoned Pharma Executive Dr. Mohammad Azab to its Board of Directors
Via TheNewswire.com
Topics Retirement
Exposures Pension
Sernova KOL Event Highlights Novel Cell Therapy Approach for the Potential Treatment of Thyroid Disease
Via TheNewswire.com
Sernova to Host a Virtual Key Opinion Leader Event on Thyroid Disease and the Potential for its Cell Therapy as a Novel Treatment Approach
Via TheNewswire.com
Sernova Appoints Internationally Renowned Thyroid Disease Expert Dr. Sam Wiseman to its Scientific Advisory Board
Via TheNewswire.com
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.